Correction: A Novel Mechanism of PPAR Gamma Induction via EGFR Signalling Constitutes Rational for Combination Therapy in Bladder Cancer

With regards to the in vivo experiment, similar results were obtained with theUM-UC13 cell line where tumor weights were only significantly reduced in the combination therapy as compared to the control group (mean weight 248 mg vs 300mg, p=0.049, see attached figure). [...]one of our main results that shows that the efficacy of combination therapy can be improved in a schedule-specific manner was conducted with three different urothelial cell lines, UM-UC3, UM-UC6 and UM-UC13. [...]the report about the cross-contamination of KU-7 does not affect our findings.